The origins of type 1 diabetes are rooted in the pancreas, an organ often characterized as a conflict zone between insulin-producing beta cells and wayward immune cells. Researchers have long been on a quest to identify this internal conflict early enough to thwart a chronic condition that drains the body’s insulin supply.
On Wednesday, Science Translational Medicine published two new studies shedding light on changes within beta cells before type 1 diabetes develops. Using experiments with human cells and mouse models, researchers employed biosensors and genetic analysis to illuminate these processes and explore potential interventions to prevent beta-cell destruction.
The first study, conducted by a team at the Indiana University School of Medicine, investigated how specific immune cells involved in inflammation, known as signaling cytokine interferon-alpha, typically prompt beta cells to generate other molecules that influence inflammation, cell growth, and cell death. These molecules, called reactive oxygen species (ROS), can sometimes cause unintended damage. However, in cells from individuals with type 1 diabetes, ROS-producing beta cells were absent, indicating a lack of cytokines to stimulate ROS production. The study authors speculated that this deficiency could serve as an early indicator of beta-cell decline in type 1 diabetes.Â
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
View All Plans

